sábado, 14 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

Uber: From Cash Burner to Cash-Flow Utility

View original at finance.yahoo.com
Uber: From Cash Burner to Cash-Flow Utility This article first appeared on GuruFocus. It has been a fascinating journey watching Uber Technologies evolve from a cash-incinerating startup into what I now consider a dominant, cash-generating utility…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Instant Retail vertical is running at a $12 billion annualized gross bookings rate

    80% confidence
  • Uber accumulated roughly $32 billion in operating losses prior to mid-2023

    80% confidence
  • Uber is positioning itself to be the essential infrastructure to the autonomous future rather than an inevitable loser in the robotaxi wars

    80% confidence
  • Management describes the gap between Adjusted EBITDA and operating income as due to one-off or non-recurring items, specifically legal reserves, regulatory settlements, and volatility in insurance reserves

    80% confidence
  • Waymo vehicles on Uber network in Phoenix and San Francisco are seeing utilization rates significantly higher than human-driven cars

    80% confidence
  • Suburban markets are growing 1.5 to 3 times faster than core metro areas

    80% confidence
  • Restaurant delivery represents a $2 trillion Total Addressable Market while general commerce represents a $12 trillion TAM

    80% confidence
  • Uber operates the largest mobility and delivery network on the planet with nearly 190 million monthly active platform consumers across 70 countries

    80% confidence
  • Rating Uber stock a Buy with high-conviction accumulation zone between $70 and $80, with 12 to 18 month price target at $110, implying roughly 35-40% upside

    80% confidence
  • Uber has scaled its advertising business to over $1 billion in annualized revenue

    80% confidence
  • In Uber's top 10 markets, only about 15% of the adult population uses the service

    80% confidence
  • Only about 20% of Uber's user base utilizes both the Mobility and Delivery platforms, but users who engage with both verticals spend roughly three times more than single-platform users

    80% confidence
  • Uber expects to grow Gross Bookings in the mid-teens and EBITDA in the high-30s to 40% range

    80% confidence

Data points we hold from this source

Uber Technologies · instant retail gross bookings12 billion_USD
Uber Technologies · adjusted ebitda2.3 billion_USD
Uber Technologies · adjusted ebitda growth33 percent
Uber Technologies · advertising revenue1 billion_USD
Uber Technologies · autonomous vehicle partnerships14 partnerships
Uber Technologies · cross platform usage rate20 percent
Uber Technologies · daily trips38 million
Uber Technologies · deferred tax asset release4 billion_USD
Uber Technologies · delivery bookings growth24 percent
Uber Technologies · free cash flow9 billion_USD
Uber Technologies · gross bookings growth21 percent
Uber Technologies · market penetration top 10 markets15 percent
Uber Technologies · monthly active platform consumers190 million
Uber Technologies · net income16 billion_USD
Uber Technologies · operating countries70 countries
Uber Technologies · operating income1.1 billion_USD
Uber Technologies · revenue13.5 billion_USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Uber: From Cash Burner to Cash-Flow Utility — Source | Via News | es.VIA.NEWS